JP2014508782A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014508782A5 JP2014508782A5 JP2013557943A JP2013557943A JP2014508782A5 JP 2014508782 A5 JP2014508782 A5 JP 2014508782A5 JP 2013557943 A JP2013557943 A JP 2013557943A JP 2013557943 A JP2013557943 A JP 2013557943A JP 2014508782 A5 JP2014508782 A5 JP 2014508782A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- antibody
- tumor
- estrogen receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000015694 estrogen receptors Human genes 0.000 claims description 28
- 108010038795 estrogen receptors Proteins 0.000 claims description 28
- 206010028980 Neoplasm Diseases 0.000 claims description 22
- 229940122815 Aromatase inhibitor Drugs 0.000 claims description 20
- 239000003886 aromatase inhibitor Substances 0.000 claims description 20
- 201000011510 cancer Diseases 0.000 claims description 16
- 102000048238 Neuregulin-1 Human genes 0.000 claims description 15
- 108090000556 Neuregulin-1 Proteins 0.000 claims description 15
- 238000002560 therapeutic procedure Methods 0.000 claims description 12
- 230000004913 activation Effects 0.000 claims description 10
- 229960003881 letrozole Drugs 0.000 claims description 10
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims description 10
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 claims description 8
- 229940102550 Estrogen receptor antagonist Drugs 0.000 claims description 8
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 8
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 8
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 8
- 229960000255 exemestane Drugs 0.000 claims description 8
- 239000000833 heterodimer Substances 0.000 claims description 8
- 238000012360 testing method Methods 0.000 claims description 8
- 229940046836 anti-estrogen Drugs 0.000 claims description 7
- 230000001833 anti-estrogenic effect Effects 0.000 claims description 7
- 238000001574 biopsy Methods 0.000 claims description 7
- 239000000328 estrogen antagonist Substances 0.000 claims description 7
- 230000002401 inhibitory effect Effects 0.000 claims description 7
- 230000026731 phosphorylation Effects 0.000 claims description 7
- 238000006366 phosphorylation reaction Methods 0.000 claims description 7
- CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 claims description 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 6
- 229960003437 aminoglutethimide Drugs 0.000 claims description 6
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 claims description 6
- 229950011548 fadrozole Drugs 0.000 claims description 6
- 229960004421 formestane Drugs 0.000 claims description 6
- OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 claims description 6
- 150000002596 lactones Chemical class 0.000 claims description 6
- 229960002932 anastrozole Drugs 0.000 claims description 5
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims description 5
- -1 lasofoxone Chemical compound 0.000 claims description 5
- 230000001404 mediated effect Effects 0.000 claims description 5
- DODQJNMQWMSYGS-QPLCGJKRSA-N 4-[(z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-phenylbut-1-en-2-yl]phenol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 DODQJNMQWMSYGS-QPLCGJKRSA-N 0.000 claims description 4
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 claims description 4
- MCGDSOGUHLTADD-UHFFFAOYSA-N arzoxifene Chemical compound C1=CC(OC)=CC=C1C1=C(OC=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 MCGDSOGUHLTADD-UHFFFAOYSA-N 0.000 claims description 4
- 229950005529 arzoxifene Drugs 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 4
- 229960002258 fulvestrant Drugs 0.000 claims description 4
- 229960004622 raloxifene Drugs 0.000 claims description 4
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 claims description 4
- 229960001603 tamoxifen Drugs 0.000 claims description 4
- 229960005026 toremifene Drugs 0.000 claims description 4
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 230000012010 growth Effects 0.000 claims description 3
- 206010029098 Neoplasm skin Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 238000001802 infusion Methods 0.000 claims description 2
- 238000010253 intravenous injection Methods 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000037841 lung tumor Diseases 0.000 claims description 2
- 230000002611 ovarian Effects 0.000 claims description 2
- 230000002018 overexpression Effects 0.000 claims description 2
- 239000003087 receptor blocking agent Substances 0.000 claims description 2
- 210000004881 tumor cell Anatomy 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 230000007704 transition Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 47
- 239000000203 mixture Substances 0.000 description 21
- 239000003112 inhibitor Substances 0.000 description 10
- 239000002246 antineoplastic agent Substances 0.000 description 7
- 208000018819 hormone-resistant breast carcinoma Diseases 0.000 description 6
- 229940124302 mTOR inhibitor Drugs 0.000 description 6
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 6
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 4
- 229960005167 everolimus Drugs 0.000 description 4
- 229940121647 egfr inhibitor Drugs 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- BUROJSBIWGDYCN-GAUTUEMISA-N AP 23573 Chemical compound C1C[C@@H](OP(C)(C)=O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 BUROJSBIWGDYCN-GAUTUEMISA-N 0.000 description 2
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical group C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 2
- 229960002087 pertuzumab Drugs 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
- 229960001302 ridaforolimus Drugs 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
- 229960002930 sirolimus Drugs 0.000 description 2
- 150000003384 small molecules Chemical group 0.000 description 2
- 229960000235 temsirolimus Drugs 0.000 description 2
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 2
- 239000002525 vasculotropin inhibitor Substances 0.000 description 2
- SYYMNUFXRFAELA-BTQNPOSSSA-N 4-[4-[[(1r)-1-phenylethyl]amino]-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenol;hydrobromide Chemical compound Br.N([C@H](C)C=1C=CC=CC=1)C(C=1C=2)=NC=NC=1NC=2C1=CC=C(O)C=C1 SYYMNUFXRFAELA-BTQNPOSSSA-N 0.000 description 1
- 241000234671 Ananas Species 0.000 description 1
- 102100030011 Endoribonuclease Human genes 0.000 description 1
- 101710199605 Endoribonuclease Proteins 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
- 229940124647 MEK inhibitor Drugs 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- KFHMLBXBRCITHF-UHFFFAOYSA-N PD158780 Chemical compound N1=CN=C2C=NC(NC)=CC2=C1NC1=CC=CC(Br)=C1 KFHMLBXBRCITHF-UHFFFAOYSA-N 0.000 description 1
- 239000012828 PI3K inhibitor Substances 0.000 description 1
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 229960001686 afatinib Drugs 0.000 description 1
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 description 1
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 239000003909 protein kinase inhibitor Substances 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- GFNNBHLJANVSQV-UHFFFAOYSA-N tyrphostin AG 1478 Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=CC(Cl)=C1 GFNNBHLJANVSQV-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161451848P | 2011-03-11 | 2011-03-11 | |
| US61/451,848 | 2011-03-11 | ||
| US201261604281P | 2012-02-28 | 2012-02-28 | |
| US61/604,281 | 2012-02-28 | ||
| PCT/US2012/028792 WO2012125573A2 (en) | 2011-03-11 | 2012-03-12 | Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014508782A JP2014508782A (ja) | 2014-04-10 |
| JP2014508782A5 true JP2014508782A5 (cg-RX-API-DMAC7.html) | 2015-04-30 |
Family
ID=45894680
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013557943A Pending JP2014508782A (ja) | 2011-03-11 | 2012-03-12 | ホルモン不応性乳癌の治療におけるｅｇｆｒファミリー受容体の阻害剤の使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20140134170A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2683741A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2014508782A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20140044796A (cg-RX-API-DMAC7.html) |
| CN (1) | CN103562226A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2012229147B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112013022882A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2828075A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA201300996A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2013010379A (cg-RX-API-DMAC7.html) |
| SG (1) | SG192844A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012125573A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101598229B1 (ko) | 2007-02-16 | 2016-02-26 | 메리맥 파마슈티컬즈, 인크. | Ｅｒｂｂ3에 대한 항체 및 이의 용도 |
| SG183532A1 (en) * | 2010-03-11 | 2012-09-27 | Merrimack Pharmaceuticals Inc | Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers |
| US9155802B2 (en) | 2010-11-01 | 2015-10-13 | Symphogen A/S | Pan-HER antibody composition |
| KR101933990B1 (ko) | 2012-05-02 | 2018-12-31 | 심포젠 에이/에스 | 인간화 ｐａｎｈｅｒ 항체 조성물 |
| EP3087394A2 (en) | 2013-12-27 | 2016-11-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
| DK3805268T3 (da) | 2014-02-28 | 2025-01-20 | Merus Nv | Antistof, der binder erbb-2 og erbb-3 |
| US10844127B2 (en) | 2014-02-28 | 2020-11-24 | Merus N.V. | Antibodies that bind EGFR and ErbB3 |
| CN111956653B (zh) | 2014-05-08 | 2023-06-30 | 上海市生物医药技术研究院 | 双炔失碳酯组合物和疾病治疗方法 |
| EP3283068A1 (en) | 2015-04-17 | 2018-02-21 | Merrimack Pharmaceuticals, Inc. | Combination treatments with seribantumab |
| US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
| ITUB20160828A1 (it) * | 2016-02-18 | 2017-08-18 | Univ Degli Studi Genova | Utilizzo di una dieta che mima il digiuno per potenziare l'efficacia di antiestrogeni nella terapia del cancro |
| CA3011949A1 (en) * | 2016-03-15 | 2017-09-21 | Merrimack Pharmaceuticals, Inc. | Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody |
| NZ752443A (en) | 2016-10-11 | 2022-11-25 | Univ Duke | Lasofoxifene treatment of er+ breast cancer |
| CN115844877B (zh) | 2017-01-10 | 2024-07-23 | 浙江嘉驰医药开发有限公司 | 拉索昔芬调节膜结合雌激素信号的应用及治疗癌症的方法 |
| EP3600413A1 (en) | 2017-03-31 | 2020-02-05 | Merus N.V. | Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene |
| KR102744809B1 (ko) * | 2017-05-17 | 2024-12-23 | 메뤼스 엔.페. | 유방암 치료를 위한 ErbB-2/ErbB-3 이중특이적 항체와 내분비 치료의 조합 |
| PL3665198T3 (pl) | 2017-08-09 | 2025-06-09 | Merus N.V. | Przeciwciała wiążące egfr i cmet |
| WO2019185164A1 (en) | 2018-03-29 | 2019-10-03 | Hummingbird Bioscience Holdings Pte. Ltd. | Her3 antigen-binding molecules |
| CN117771239A (zh) | 2018-04-10 | 2024-03-29 | 杜克大学 | 乳腺癌的拉索昔芬治疗 |
| TW202227504A (zh) * | 2020-10-15 | 2022-07-16 | 大陸商上海翰森生物醫藥科技有限公司 | 抗ｅｒｂｂ３抗體或其抗原結合片段及其醫藥用途 |
| GB202116903D0 (en) | 2021-11-18 | 2022-01-05 | Sermonix Pharmaceuticals Inc | Lasofoxifene treatment of aromatase-resistant er+ cancer |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5183884A (en) | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| ATE483733T1 (de) | 1995-06-14 | 2010-10-15 | Univ California | Hochaffine humane antikörper gegen tumorantigene |
| US5968511A (en) | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| US7390632B2 (en) | 1999-09-30 | 2008-06-24 | Tumor Biology Investment Group, Inc. | Soluble ErbB3 receptor isoforms |
| US7638302B2 (en) | 2001-05-31 | 2009-12-29 | Tumor Biology Investment Group, Inc. | Soluble ErbB3 receptor isoforms |
| EP1283053A1 (en) | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of HER3 activity |
| CA2480099C (en) | 2002-03-26 | 2019-01-08 | Zensun (Shanghai) Sci-Tech. Ltd. | Erbb3 based methods and compositions for treating neoplasms |
| US7332585B2 (en) * | 2002-04-05 | 2008-02-19 | The Regents Of The California University | Bispecific single chain Fv antibody molecules and methods of use thereof |
| US7332580B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The University Of California | Bispecific single chain Fv antibody molecules and methods of use thereof |
| AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| KR101598229B1 (ko) | 2007-02-16 | 2016-02-26 | 메리맥 파마슈티컬즈, 인크. | Ｅｒｂｂ3에 대한 항체 및 이의 용도 |
| DK2132229T3 (en) | 2007-03-01 | 2016-06-20 | Symphogen As | Recombinant anti-epidermal growth factor receptor-ANTIBODY COMPOSITIONS |
| BRPI0811156A2 (pt) | 2007-05-11 | 2019-09-24 | Enzon Pharmaceuticals Inc | compostos antagonistas de rna para a modulação de her3 |
| EP2860260A1 (en) * | 2008-04-11 | 2015-04-15 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
| AU2009281721A1 (en) | 2008-08-15 | 2010-02-18 | Merrimack Pharmaceuticals, Inc. | Methods and systems for predicting response of cells to a therapeutic agent |
| KR20110112301A (ko) * | 2008-11-18 | 2011-10-12 | 메리맥 파마슈티컬즈, 인크. | 인간 혈청 알부민 링커 및 그 콘쥬게이트 |
| NZ594665A (en) | 2009-03-20 | 2013-08-30 | Genentech Inc | Bispecific anti-her antibodies |
| US8362215B2 (en) | 2009-04-29 | 2013-01-29 | Trellis Bioscience, Llc | Antibodies immunoreactive with heregulin-coupled HER3 |
| WO2011047180A1 (en) * | 2009-10-14 | 2011-04-21 | Merrimack Pharmaceuticals, Inc. | Bispecific binding agents targeting igf-1r and erbb3 signalling and uses thereof |
| SG183532A1 (en) * | 2010-03-11 | 2012-09-27 | Merrimack Pharmaceuticals Inc | Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers |
| US8481687B2 (en) | 2010-04-09 | 2013-07-09 | Aveo Pharmaceuticals, Inc. | Anti-ErbB3 antibodies |
| US9011863B2 (en) * | 2010-07-09 | 2015-04-21 | Exelixis, Inc. | Combinations of kinase inhibitors for the treatment of cancer |
-
2012
- 2012-03-12 BR BR112013022882A patent/BR112013022882A2/pt not_active IP Right Cessation
- 2012-03-12 EP EP12711080.7A patent/EP2683741A2/en not_active Withdrawn
- 2012-03-12 SG SG2013062856A patent/SG192844A1/en unknown
- 2012-03-12 MX MX2013010379A patent/MX2013010379A/es unknown
- 2012-03-12 CA CA2828075A patent/CA2828075A1/en not_active Abandoned
- 2012-03-12 JP JP2013557943A patent/JP2014508782A/ja active Pending
- 2012-03-12 WO PCT/US2012/028792 patent/WO2012125573A2/en not_active Ceased
- 2012-03-12 CN CN201280012969.XA patent/CN103562226A/zh active Pending
- 2012-03-12 EA EA201300996A patent/EA201300996A1/ru unknown
- 2012-03-12 US US14/004,598 patent/US20140134170A1/en not_active Abandoned
- 2012-03-12 AU AU2012229147A patent/AU2012229147B2/en not_active Ceased
- 2012-03-12 KR KR1020137026392A patent/KR20140044796A/ko not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014508782A5 (cg-RX-API-DMAC7.html) | ||
| US9518130B2 (en) | Use of ERBB3 inhibitors in the treatment of triple negative and basal-like breast cancers | |
| Prenen et al. | Role of targeted agents in metastatic colorectal cancer | |
| AU2012229147B2 (en) | Use of inhibitors of EGFR-family receptors in the treatment of hormone refractory breast cancers | |
| JP6829193B2 (ja) | がんを治療するための単独または併用療法におけるｃｃｒ５拮抗剤の使用 | |
| JP2023502585A (ja) | 癌の治療のための、ＰＤ－１、ＴＧＦβ、及びＴＩＧＩＴの組み合わせ阻害 | |
| CA3060407A1 (en) | Treatment of her2 positive cancers | |
| EP3553083A1 (en) | Combination therapy for the treatment of ovarian cancer | |
| JP2019517498A (ja) | 再発性小細胞肺癌の処置方法において使用するための抗ｐｄ−１抗体 | |
| JP2024513505A (ja) | 腫瘍を治療するための組成物及び方法 | |
| JP2017534574A (ja) | チロシンキナーゼ阻害薬（ｔｋｉ）に耐性のがんを処置するための組成物および方法 | |
| AU2010236818B2 (en) | Combination therapy using an anti-EGFR agent(s) and IGF-1R specific inhibitors | |
| US20230250182A1 (en) | Methods for treating cancer or von-hippel lindau disease using a combination of a pd-1 antagonist, a hif-2 alpha inhibitor, and lenvatinib or a pharmaceutically acceptable salt thereof | |
| JP6712226B2 (ja) | エキセメスタン及びエベロリムスと組み合わせてインスリン様成長因子（ｉｇｆ）受容体アンタゴニストを用いる癌治療 | |
| WO2025245489A1 (en) | Treatment of tumors in subjects having fgl-1 positive samples | |
| JP2024511995A (ja) | がん治療における第一選択療法としてのｓＥｐｈＢ４－ＨＳＡ融合タンパク質の使用 | |
| WO2023230429A1 (en) | Methods of treating colorectal cancer with tucatinib in combination with an anti-her2 antibody | |
| TWI500630B (zh) | 具有細胞生長抑制功效之表皮生長因子受體（ｅｇｆｒ）抑制劑類及彼等於腫瘤治療上之用途 | |
| KR20240093915A (ko) | 모수네투주맙 및 레날리도마이드를 이용한 재발성/불응성 소포 림프종의 치료 방법 | |
| NZ614427B2 (en) | Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers | |
| Shabaya et al. | Novel therapeutic strategies and combinations for HER2-overexpressing breast cancer | |
| Garca‐Saénz et al. | Pertuzumab (Perjeta®) |